Abstract
Objectives
To adapt the supranational European Federation for Periodontology (EFP) S3-Level Clinical Practice Guideline for treatment of periodontitis (stage I-III) to a UK healthcare environment, taking into account the views of a broad range of stakeholders, and patients.
Sources
This UK version is based on the supranational EFP guideline (Sanz et al., 2020) published in the Journal of Clinical Periodontology. The source guideline was developed using the S3-level methodology, which combined the assessment of formal evidence from 15 systematic reviews with a moderated consensus process of a representative group of stakeholders, and accounts for health equality, environmental factors and clinical effectiveness. It encompasses 62 clinical recommendations for the treatment of stage I–III periodontitis, based on a step-wise process mapped to the 2017 classification system.
Methodology
The UK version was developed from the source guideline using a formal process called the GRADE ADOLOPMENT framework. This framework allows for the adoption (unmodified acceptance), adaptation (acceptance with modifications) and the de novo development of clinical recommendations. Using this framework and following the S3-process, the underlying systematic reviews were updated and a representative guideline group of 75 delegates from 17 stakeholder organisations was assembled into three working groups. Following the formal S3-process, all clinical recommendations were formally assessed for their applicability to the UK and adoloped accordingly.
Results and conclusion
Using the ADOLOPMENT protocol, a UK version of the EFP S3-level clinical practice guideline was developed. This guideline delivers evidence- and consensus-based clinical recommendations of direct relevance to the dental community in the UK.
Clinical significance
The aim of S3-level guidelines is to combine the evaluation of formal evidence, grading and synthesis with the clinical expertise of a broad range of stakeholders to form clinical recommendations. Herein, the first major international S3-level guideline in dentistry, the EFP guideline, was implemented for direct clinical applicability in the UK healthcare system.
To adapt the supranational European Federation for Periodontology (EFP) S3-Level Clinical Practice Guideline for treatment of periodontitis (stage I-III) to a UK healthcare environment, taking into account the views of a broad range of stakeholders, and patients.
Sources
This UK version is based on the supranational EFP guideline (Sanz et al., 2020) published in the Journal of Clinical Periodontology. The source guideline was developed using the S3-level methodology, which combined the assessment of formal evidence from 15 systematic reviews with a moderated consensus process of a representative group of stakeholders, and accounts for health equality, environmental factors and clinical effectiveness. It encompasses 62 clinical recommendations for the treatment of stage I–III periodontitis, based on a step-wise process mapped to the 2017 classification system.
Methodology
The UK version was developed from the source guideline using a formal process called the GRADE ADOLOPMENT framework. This framework allows for the adoption (unmodified acceptance), adaptation (acceptance with modifications) and the de novo development of clinical recommendations. Using this framework and following the S3-process, the underlying systematic reviews were updated and a representative guideline group of 75 delegates from 17 stakeholder organisations was assembled into three working groups. Following the formal S3-process, all clinical recommendations were formally assessed for their applicability to the UK and adoloped accordingly.
Results and conclusion
Using the ADOLOPMENT protocol, a UK version of the EFP S3-level clinical practice guideline was developed. This guideline delivers evidence- and consensus-based clinical recommendations of direct relevance to the dental community in the UK.
Clinical significance
The aim of S3-level guidelines is to combine the evaluation of formal evidence, grading and synthesis with the clinical expertise of a broad range of stakeholders to form clinical recommendations. Herein, the first major international S3-level guideline in dentistry, the EFP guideline, was implemented for direct clinical applicability in the UK healthcare system.
| Original language | English |
|---|---|
| Article number | 103562 |
| Number of pages | 72 |
| Journal | Journal of Dentistry |
| Volume | 106 |
| Early online date | 8 Feb 2021 |
| DOIs | |
| Publication status | Published - 1 Mar 2021 |
Bibliographical note
Funding Information:Dr. Tonetti, Maurizio (Chair) reports personal fees from Geistlich Pharma AG, Procter & Gamble, Straumann AG, Sunstar SA, Unilever; grants from Geistlich Pharma, Sunstar SA; non-financial support from Procter & Gamble, outside the submitted work.
Funding Information:
Dr. Sanz, Mariano (Chair) reports personal fees from Camlog implants, Colgate, Dentium Implants, Dentsply Sirona Implants, Geistlich, GSK, Klockner Implants, MIS Implants, Mozo Grau Implants, Nobel Biocare, Procter & Gamble, Straumann, Sunstar; grants from Camlog Implants, Dentaid, Dentium Implants, Dentsply Sirona Implants, Geistlich Pharma, Klockner Implants, MIS Implants, Mozo Grau Implants, Nobel Biocare, Sunstar, Straumann AG, Sweden and Martina Implants; and other support from Dentaid, outside the submitted work.
Funding Information:
Dr. Sculean, Anton (Chair) reports personal fees from Botiss Biomaterials, Geistlich Pharma, Oral Reconstruction Foundation, Osteology Foundation, Straumann AG, Regedent AG, Stoma; grants from Botiss Biomaterials, Geistlich Pharma, ITI Foundation, Oral Reconstruction Foundation, Osteology Foundation, Straumann AG, Regedent AG; outside the submitted work.
Funding Information:
Dr. Chapple, Iain (Chair) reports personal fees from Procter & Gamble; grants from GSK, Unilever, outside the submitted work. In addition, Dr. Chapple has 8 patents on saliva diagnostics issued and his wife runs Oral Health Innovations that has the license for PreViser and DEPPA risk assessment software in the UK.
Funding Information:
Dr. Berglundh, Tord (Chair) reports personal fees from Dentsply Sirona Implants, Straumann; grants from Dentsply Sirona Implants, outside the submitted work.
Funding Information:
The authors express their gratitude to all reviewers involved in the preparation of the systematic reviews. In addition, we wish to thank the organisations which agreed to participate in the guideline ADOLOPMENT process: British Endodontic Society, British Society of Restorative Dentistry, Restorative Dentistry UK, British Association of Dental Therapists, British Dental Association, British Dental Journal, British Society of Dental Hygiene and Therapy, BSP Patient Forum, Dental Health Organisation, Dental Protection, Faculty of General Dental Practice (UK),General Dental Council, NHS England and NHS Improvement, Public Health England, Royal College of Surgeons of England. We are extremely grateful that no organisations we approached declined to take part in this process.
Funding Information:
Dr. Herrera, David (Chair) reports personal fees from Colgate, Dentaid, Dexcel Pharma, GSK, Johnson & Johnson, Klockner Implants, Procter & Gamble, Straumann; grants from Colgate, Dentaid, GSK, Kulzer, Zimmer-Biomet, outside the submitted work. Other relationships or activities reported: Trustee of the Foundation of the Spanish Society of Periodontology, board member of the Continental European Division of the International Association of Periodontology, committee member of the Postgraduate Education Committee of the European Federation of Periodontology (EFP), committee member of the European Workshop Committee of the European Federation of Periodontology (EFP), expert in the Global Periodontal Health Project (FDI World Dental Federation); Specific interest in periodontal therapy, as periodontist practising on a daily basis, and in periodontal therapy, as main interest in research.
Publisher Copyright:
© 2021 The Authors
Keywords
- Stage
- Grade
- Clinical Guideline
- Periodontal Therapy
- Health Policy
- Oral Health
Access to Document
- Full-text PDF (final published version)
This is the final published version of the article (version of record). It first appeared online via Elsevier at https://doi.org/10.1016/j.jdent.2020.103562 . Please refer to any applicable terms of use of the publisher.
Handle.net
Full-text PDF (author’s accepted manuscript)
Accepted author manuscript, 1.95 MB